“From a mechanistic standpoint, we believe we co

Quote:

---

“From a mechanistic standpoint, we believe we could get a synergistic effect with a checkpoint inhibitor,” he said.

Leronlimab is currently being trialed in combination with Keytruda (pembrolizumab) in a breast cancer xenograft model in partnership with MD Anderson Cancer Center

---

Correct me if I'm wrong, Ohm, but I'm pretty sure you (Ohm) once said that Leron and a checkpoint inhibitor together would be redundant -- that Leron does what a checkpoint inhibitor does, and much more.

So if I remember this correctly either Ohm is right or Cyrus is right. I'd put my money on Ohm.